Si presenta la prima versione di FarmaRegio, modello econometrico per l'analisi della variabilità regionale della spesa farmaceutica territoriale convenzionata (un panel ad effetti casuali). Si suggeriscono due prospettive di lettura: da un lato, la valutazione della significatività delle...

Il Quaderno contiene una dettagliata ricostruzione dell'evoluzione del quadro normativo relativo agli strumenti di copertura della spesa privata per sanità e assistenza alla persona: dall'out-of-pocket, ai fondi sanitari vecchi e nuovi, alle società di mutuo soccorso, alle assicurazioni. Le...

Nei prossimi decenni tutti i Paesi ad economia e welfare sviluppati dovranno fronteggiare spese sanitarie fortemente crescenti, con trend potenziali che nel lungo periodo, al 2050-2060, potrebbero raddoppiare o più che raddoppiare l'incidenza della componente pubblica sul Pil. Così emerge...

Spending for Medicare's prescription drug program (Part D) was $50 billion in 2013—about 50 percent less than CBO projected when the program was created. Lower growth rates in national drug spending and lower-than-expected enrollment primarily account for the difference. The competitive design...

Ontario healthcare reforms have made headway in improving access to primary care by implementing the “capitation” model where doctors are paid mainly for a roster of patients rather than fee-for-service – but too many of patients are still using “outside” doctors, according to a report...

Throughout history the development of medical institution was followed by the extension of medical expertise boundaries. Progress in new medical biotechnologies and the manipulation of human biological material, in particular, raise the conceptual question of how to define the boundaries between...

Contrary to the traditional view of the health care consumer as an economic agent whose sove-reignty is attenuated, we argue that he is far less ignorant and far less deprived of reason than it is supposed by the tutelary model of health economics. The reason lies in his enhanced level of...

Most beneficiaries of Medicare's Part D prescription drug insurance choose among private drug plans to receive their coverage. This paper is the first to examine the relationship between the number of competing plan sponsors and the cost of Part D during the program's first five years. Over the...

By Andrew Stocking (CBO), James Baumgardner (CBO), Melinda Buntin (Vanderbilt University), and Anna Cook (CBO) The structure of the Medicare Part D prescription drug program generally encourages plan sponsors to submit low bids. However, rules in the program relating to low-income beneficiaries...